 |
市場調査レポート
商品コード
1519372
ヘモグロビン異常症の市場レポート：タイプ別、治療法別、検査タイプ別、エンドユーザー別、地域別、2024年～2032年Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2024-2032 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
| ヘモグロビン異常症の市場レポート：タイプ別、治療法別、検査タイプ別、エンドユーザー別、地域別、2024年～2032年 |
|
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 図表
- 目次
世界のヘモグロビン異常症の市場規模は2023年に101億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけての成長率（CAGR）は8.5％を示し、2032年には213億米ドルに達すると予測しています。製薬会社、ヘルスケアプロバイダー、研究機関の戦略的提携やパートナーシップの増加、個別化医療へのシフトの進展、規制当局の支援や有利な償還政策の実施などが、市場成長を促進する主な要因となっています。
ヘモグロビン異常症は、全身に酸素を運ぶ赤血球の適切な機能に不可欠なヘモグロビン分子に影響を及ぼす遺伝子疾患群です。これらの疾患は主に、サラセミアと鎌状赤血球貧血のような異常ヘモグロビン変異体の2種類に分類されます。サラセミアは、ヘモグロビンを構成するグロビン鎖の1本の産生量が減少する突然変異に起因し、バランスが崩れて貧血になります。一方、鎌状赤血球貧血のような疾患は、ヘモグロビン分子自体の形や機能に異常をきたす突然変異によって引き起こされます。異常な形状により赤血球が硬くなり、細い血管を通りにくくなるため、酸素の分配に影響を及ぼします。ヘモグロビン異常症は遺伝性であることが多く、疲労、脱力感、ひどい場合には臓器障害など、軽度から重度までさまざまな症状を引き起こします。
ヘモグロビン血症に対する人々の意識の高まりが、世界市場を大きく牽引しています。ヘモグロビン異常症に焦点を当てた団体は、政策変更、資金援助、患者ケアの改善などを求めるロビー活動でますます効果を上げています。また、一般市民を教育することで、早期診断と早期治療を促進する上でも極めて重要です。ヘルスケアシステムがより強固で利用しやすくなるにつれて、ヘモグロビン異常症のような特殊な疾患の診断・治療能力も向上しています。新しい診療所や病院には先進的な診断技術が導入され、より多くの患者集団に対応できるようになっています。これとともに、製薬会社、ヘルスケアプロバイダー、調査機関の戦略的提携や協力関係も、ヘモグロビン異常症産業の成長を後押ししています。さらに、個別化医療が重視されるようになっていることも、ヘモグロビン異常症の市場にプラスの影響を与える要因の一つです。個別化医療とは、個々の患者の特性に合わせた治療を行うことです。個別化医療へのシフトは、専門的な診断検査や治療の需要に影響を与え、市場の成長をさらに促進しています。さらに、規制当局の支援や有利な償還政策の実施により、市場の見通しは明るいです。
ヘモグロビン異常症の市場傾向/促進要因：
ヘモグロビン異常の有病率の増加
ヘモグロビン異常症業界を牽引する最も重要な要因の一つは、鎌状赤血球貧血、サラセミア、その他の希少変異型などのヘモグロビン異常症の有病率の上昇です。これらの疾患は特定の民族集団や地域で流行しているが、世界の移民パターンにより、より広範な人口に見られるようになってきています。歴史的に罹患率の低かった国々でも、現在では多くの症例が報告されるようになり、これらの疾患を管理するためのヘルスケア・インフラの改善が必要となっています。認知度が向上し、診断率が高まるにつれ、専門的な治療、診断、管理計画に対する需要も増加しています。さらに、ヘモグロビン異常症を認識し治療するためのトレーニングを受けるヘルスケアプロバイダーが増えており、市場の成長をさらに促進しています。これらすべての要因が、薬物療法、診断機器、遺伝子検査キット、ヘモグロビン異常症に特化した専門的ヘルスケアサービスに対するニーズの増加に寄与し、業界の成長を促進しています。
診断と治療における技術の進歩
ヘモグロビン異常症産業のもう一つの重要な促進要因は、診断方法と治療の両方における技術的進歩です。新生児スクリーニングによる早期診断や、高速液体クロマトグラフィー（HPLC）や分子生物学的手法を含む高度な診断ツールは、この疾患のより良い管理につながっています。これとともに、遺伝子治療、CRISPR技術、薬剤製剤の改良などの治療法の進歩も、ヘモグロビン異常症のより効果的な管理に道を開いています。こうした技術革新は、患者の予後を向上させるだけでなく、市場関係者が研究開発に投資する原動力にもなっています。技術の進化に伴い、より正確で迅速な診断ツールや、潜在的に治癒可能な治療法の登場が予想され、業界の需要拡大と拡大が促進されます。
政府の取り組みと資金調達
政府の取り組みもまた、ヘモグロビン異常症業界にとって重要な市場促進要因です。世界中の様々な政府が、ヘモグロビン異常症が公衆衛生に与える影響を認識するようになっており、ヘモグロビン異常症に対処するための的を絞ったプログラムを立ち上げつつあります。さらに、研究への資金提供、一般市民への啓発キャンペーン、国家ヘルスケア計画へのヘモグロビン異常症スクリーニングの組み込みは、そのような取り組みの一例です。こうした措置は、診断率を高めるだけでなく、より多くの人々が治療を受けやすくします。また、製薬会社や研究開発機関に対する治療法開発のための特別助成金や財政支援も用意されています。このような取り組みやこの分野への資金投入は、需要と供給の両方を大幅に強化し、市場の成長を促進します。
目次
第1章 序文
第2章 調査範囲と調査手法
- 調査の目的
- ステークホルダー
- データソース
- 一次情報
- 二次情報
- 市場推定
- ボトムアップアプローチ
- トップダウンアプローチ
- 調査手法
第3章 エグゼクティブサマリー
第4章 イントロダクション
- 概要
- 主要業界動向
第5章 世界のヘモグロビン異常症市場
- 市場概要
- 市場実績
- COVID-19の影響
- 市場予測
第6章 市場内訳：タイプ別
- サラセミア
- 市場動向
- 主要セグメント
- アルファサラセミア
- ベータサラセミア
- 市場予測
- 鎌状赤血球症
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
第7章 市場内訳：治療法別
- 輸血
- 市場動向
- 市場予測
- 幹細胞移植
- 市場動向
- 市場予測
- 鎮痛剤
- 市場動向
- 市場予測
- 抗生物質
- 市場動向
- 市場予測
- ACE阻害薬
- 市場動向
- 市場予測
- ヒドロキシウレア
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
第8章 市場内訳：検査タイプ別
- 赤血球数（RBC）
- 市場動向
- 市場予測
- 遺伝子検査
- 市場動向
- 市場予測
- 高速液体クロマトグラフィー（HPLC）
- 市場動向
- 市場予測
- ヘモグロビン等電点電気泳動（Hb IEF）
- 市場動向
- 市場予測
- ヘモグロビン電気泳動（Hb ELP）
- 市場動向
- 市場予測
- ヘモグロビン溶解度試験
- 市場動向
- 市場予測
第9章 市場内訳：エンドユーザー別
- 病院と診療所
- 市場動向
- 市場予測
- 診断研究所
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
第10章 市場内訳：地域別
- 北米
- 米国
- カナダ
- アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
- 欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
- ラテンアメリカ
- ブラジル
- メキシコ
- その他
- 中東・アフリカ
- 市場動向
- 市場内訳：国別
- 市場予測
第11章 SWOT分析
- 概要
- 強み
- 弱み
- 機会
- 脅威
第12章 バリューチェーン分析
第13章 ポーターのファイブフォース分析
- 概要
- 買い手の交渉力
- 供給企業の交渉力
- 競合の程度
- 新規参入業者の脅威
- 代替品の脅威
第14章 価格分析
第15章 競合情勢
- 市場構造
- 主要企業
- 主要企業のプロファイル
- Bio-Rad Laboratories Inc.
- bluebird bio Inc.
- Bristol-Myers Squibb Company
- Danaher Corporation
- Emmaus Life Sciences Inc.
- Gamida-Cell Ltd.
- Global Blood Therapeutics Inc.
- Novartis AG
- PerkinElmer Inc.
- Pfizer Inc.
- Prolong Pharmaceuticals LLC
- Sangamo Therapeutics Inc.
- Sysmex Corporation
List of Figures
- Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
- Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2023
- Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2023
- Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2023
- Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2023
- Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2023
- Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2023
- Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
- Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
- Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2023 and 2032
- Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million US$), 2024-2032
- Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million US$), 2024-2032
- Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
- Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million US$), 2024-2032
- Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 7: Global: Hemoglobinopathies Market: Competitive Structure
- Table 8: Global: Hemoglobinopathies Market: Key Players
The global hemoglobinopathies market size reached US$ 10.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.3 Billion by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032. The rising strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions, the growing shift toward personalized medicine, and the implementation of regulatory support and favorable reimbursement policies are among the key factors driving the market growth.
Hemoglobinopathies are a group of genetic disorders that affect the hemoglobin molecule, which is crucial for the proper function of red blood cells in carrying oxygen throughout the body. These disorders can be categorized mainly into two types: thalassemias and abnormal hemoglobin variants, such as sickle cell anemia. Thalassemias result from mutations that reduce the production of one of the globin chains that make up hemoglobin, leading to an imbalance and subsequent anemia. On the other hand, conditions such as sickle cell anemia are caused by mutations that lead to abnormal shapes or functions of the hemoglobin molecule itself. The abnormal shapes can cause red blood cells to become rigid, making it difficult for them to travel through small blood vessels, thereby affecting oxygen distribution. They are often inherited and can result in symptoms ranging from mild to severe, including fatigue, weakness, and in extreme cases, organ damage.
The growing public awareness majorly drives the global market. Organizations focused on hemoglobinopathies are increasingly effective at lobbying for policy changes, funding, and improved patient care. They are also crucial in educating the public, thereby increasing early diagnosis and treatment. As healthcare systems become more robust and accessible, the capability to diagnose and treat specialized conditions, such as hemoglobinopathies also increases. New clinics and hospitals are being equipped with advanced diagnostic technologies, thereby reaching a larger patient population. Along with this, strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions are also driving the growth of the hemoglobinopathies industry. In addition, the growing emphasis on personalized medicine is another factor that impacts the hemoglobinopathies market positively. Personalized medicine involves tailoring medical treatment to individual patient characteristics. The shift toward personalized medicine is influencing the demand for specialized diagnostic tests and treatments, further driving market growth. Moreover, the implementation of regulatory support and favorable reimbursement policies is creating a positive market outlook.
Hemoglobinopathies Market Trends/Drivers:
Increasing prevalence of hemoglobin disorders
One of the most significant drivers propelling the hemoglobinopathies industry is the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemias, and other rare variants. These disorders are prevalent in specific ethnic groups and geographical regions, but due to global migration patterns, they are increasingly found in a more widespread population. Countries with historically low incidence rates are now reporting more cases, necessitating improved healthcare infrastructure to manage these conditions. As awareness grows and diagnosis rates increase, there is a corresponding rise in demand for specialized treatments, diagnostics, and management plans. Additionally, more healthcare providers are being trained to recognize and treat hemoglobinopathies, further facilitating market growth. All these factors contribute to increased needs for medication, diagnostics equipment, genetic testing kits, and specialized healthcare services tailored for hemoglobinopathies, thereby driving the industry's growth.
Technological advancements in diagnosis and treatment
Another significant driver for the hemoglobinopathies industry is the technological advancements in both diagnostic methods and treatments. Earlier diagnosis through newborn screenings and sophisticated diagnostic tools including High-Performance Liquid Chromatography (HPLC) and molecular techniques have led to better management of the condition. Along with this, advancements in treatment methods, including gene therapy, CRISPR technology, and improved drug formulations, are also paving the way for more effective management of hemoglobin disorders. These innovations not only enhance patient outcomes but also provide an impetus for market players to invest in research and development. As the technology evolves, we can anticipate more accurate, quicker diagnostic tools and potentially curative therapies, driving greater demand and expansion in the industry.
Government Initiatives and Funding
Governmental efforts are also significant market drivers for the hemoglobinopathies industry. Various governments worldwide are increasingly acknowledging the public health impact of hemoglobin disorders and are setting up targeted programs to deal with them. In addition, funding for research, public awareness campaigns, and inclusion of hemoglobinopathy screening in national healthcare plans are examples of such initiatives. These steps not only increase the rate of diagnosis but also make treatments more accessible to a larger population. Special grants and financial support for pharmaceutical companies and research institutions for developing treatments are also available. Such initiatives and financial injections into the sector significantly bolster both demand and supply, facilitating market growth.
Hemoglobinopathies Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, treatment, test type and end user.
Breakup by Type:
Thalassemia
Alpha Thalassemia
Beta Thalassemia
Sickle Cell Disease
Others
Sickle cell disease accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes thalassemia (alpha thalassemia and beta thalassemia), sickle cell disease, and others. According to the report, sickle cell disease represented the largest segment.
The market for treating sickle cell disease (SCD), a type of hemoglobinopathy, is experiencing robust growth due to the rising incidence and awareness of SCD, particularly in African, Middle Eastern, and South Asian populations. Additionally, advancements in diagnostic techniques, including high-performance liquid chromatography (HPLC) and genetic screening are enabling earlier and more accurate detection, increasing the demand for targeted treatments. In addition, government initiatives have also played a pivotal role by incorporating SCD screenings in national healthcare plans and providing funding for research. In addition, the emergence of innovative treatment options such as gene therapies and CRISPR technology offer potential curative solutions, attracting significant investment in the sector. Furthermore, positive regulatory frameworks and reimbursement policies make treatments more accessible, thereby expanding the market.
Breakup by Treatment:
Blood Transfusion
Stem-cell Transplantation
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
A detailed breakup and analysis of the market based on the treatment has also been provided in the report. This includes blood transfusion, stem-cell transplantation, analgesics, antibiotics, ace inhibitors, hydroxyurea, and others.
The demand for blood transfusion treatment in the hemoglobinopathies industry is primarily driven by its essential role in managing severe cases of disorders, such as thalassemia and sickle cell disease. Along with this, the increasing prevalence of these conditions amplifies the need for regular transfusions, thereby fueling market growth. In addition, technological advancements in blood screening and storage have also contributed to safer and more efficient transfusion processes. Governmental initiatives, such as organized blood donation campaigns and reimbursement policies, make this treatment more accessible and cost-effective for patients. In addition, the growing interest in stem-cell transplantation as a potentially curative treatment for hemoglobinopathies, including thalassemia and sickle cell disease is a notable market driver. Moreover, technological advancements have made these procedures safer and more effective, drawing increased investment and research focus. Governmental backing in the form of grants and regulatory approval fast-tracks also bolster this sector.
On the other hand, the growing awareness and advocacy for advanced treatment options have led to higher demand for stem-cell transplantation, further propelling market growth in the hemoglobinopathies industry. Apart from this, the demand for analgesics in the hemoglobinopathies industry is driven by chronic pain. Increasing awareness and diagnosis rates further provide a boost to this market segment. The need for antibiotics in the hemoglobinopathies industry is driven by frequent bacterial infections in patients, thereby stimulating the demand for effective treatment options. Furthermore, the market for ACE inhibitors in the hemoglobinopathies industry is propelled by their role in managing kidney complications in patients.
Breakup by Test Type:
Red Blood Cell (RBC) Count
Genetic Testing
High Performance Liquid Chromatography (HPLC)
Hemoglobin Isoelectric Focusing (Hb IEF)
Hemoglobin Electrophoresis (Hb ELP)
Hemoglobin Solubility Test
The report has provided a detailed breakup and analysis of the market based on the test type. This includes red blood cell (RBC) count, genetic testing, high performance liquid chromatography (HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.
In the hemoglobinopathies industry, the market drivers for the red blood cell (RBC) count test type are significant. Hemoglobinopathies, including conditions, such as sickle cell anemia and thalassemia, necessitate frequent monitoring of RBC counts to assess disease severity and treatment efficacy. As awareness of these disorders grows, so does the demand for accurate diagnostic tools. Moreover, advancements in healthcare technology have led to more accessible and cost-effective RBC count testing methods. The combination of increased disease awareness and improved diagnostic capabilities positions the RBC count test as a critical component of the hemoglobinopathies industry, driving its market growth. Along with this, genetic testing is a key market driver in the hemoglobinopathies industry, enabling precise disease identification and personalized treatment strategies, and fostering growth and innovation.
On the other hand, high-performance liquid chromatography (HPLC) is a crucial driver in the hemoglobinopathies industry, providing precise hemoglobin analysis, enhancing diagnostics, and fostering industry advancement. Apart from this, hemoglobin isoelectric focusing (Hb IEF) plays a pivotal role in the hemoglobinopathies industry by offering precise hemoglobin analysis, driving diagnostic accuracy, and industry growth. In confluence with this, hemoglobin electrophoresis (Hb ELP) is a cornerstone in the hemoglobinopathies industry, providing precise hemoglobin analysis, driving diagnostic accuracy, and fostering industry growth. Furthermore, hemoglobin solubility testing is a critical driver in the hemoglobinopathies industry, offering efficient diagnosis and aiding in disease management, contributing to industry growth.
Breakup by End User:
Hospitals and Clinics
Diagnostics Laboratories
Others
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals and clinics, diagnostics laboratories, and others.
Diagnostics laboratories serve as a pivotal end user in the hemoglobinopathies industry, driving growth due to their central role in disease diagnosis and management. In addition, the increasing prevalence of hemoglobinopathies worldwide necessitates a higher volume of diagnostic tests, including hemoglobin analysis and genetic testing. Furthermore, ongoing research and development efforts focus on enhancing the accuracy and efficiency of diagnostic tools, further elevating the significance of diagnostics laboratories. Their expertise and technology contribute significantly to advancing our understanding of hemoglobin disorders and tailoring treatment approaches, solidifying their status as key market drivers in this industry.
On the contrary, hospitals and clinics represent crucial end users in the hemoglobinopathies industry, actively driving growth and advancement. These healthcare facilities are frontline providers of care to individuals affected by hemoglobin disorders. The growing awareness of these conditions, coupled with an increasing patient population, leads to a higher demand for diagnostic tests, genetic counseling, and specialized treatments. Hospitals and clinics play a pivotal role in providing comprehensive care, driving the need for improved diagnostic tools and therapeutic interventions. Their prominence as end users reinforces their impact as significant market drivers in the hemoglobinopathies industry.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest hemoglobinopathies market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America stands as a dynamic and influential region in the hemoglobinopathies industry, driven by the region's commitment to healthcare excellence and rigorous standards. It fuels the demand for cutting-edge diagnostic tools and therapeutic interventions. The prevalence of hemoglobin disorders, particularly sickle cell disease, within diverse populations, including African Americans and Hispanic communities, places North America at the forefront of research, diagnosis, and treatment.
Additionally, the region's robust research and development ecosystem, consisting of academic institutions, pharmaceutical companies, and biotechnology firms, fosters innovation in hemoglobinopathy diagnostics and therapies. This research-driven environment continually introduces novel diagnostic methods and treatment modalities, stimulating market growth. Furthermore, advocacy efforts and government initiatives aimed at improving healthcare access for individuals with hemoglobinopathies amplify the demand for diagnostic testing and specialized care. These initiatives include newborn screening programs and policies supporting early diagnosis and intervention.
Competitive Landscape:
The key players are investing heavily in research and development to discover new diagnostic tests, therapies, and treatment modalities. They aim to enhance the accuracy of diagnostic tools and develop innovative treatments that can improve the quality of life for individuals with hemoglobin disorders. Along with this, companies are continually developing and improving diagnostic tests for hemoglobinopathies, including advancements in techniques, such as genetic testing, high-performance liquid chromatography (HPLC), hemoglobin electrophoresis (Hb ELP), and hemoglobin isoelectric focusing (Hb IEF) is positively influencing the market. In addition, pharmaceutical companies in the hemoglobinopathies market work on the development of new therapies, including gene therapies, gene editing technologies (e.g., CRISPR), and small molecule drugs, which act as another growth-inducing factor. Furthermore, the widespread adoption of cutting-edge technologies, such as artificial intelligence and machine learning, for data analysis and improving diagnostic accuracy is contributing to the market.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Bio-Rad Laboratories Inc.
bluebird bio Inc.
Bristol-Myers Squibb Company
Danaher Corporation
Emmaus Life Sciences Inc.
Gamida-Cell Ltd.
Global Blood Therapeutics Inc.
Novartis AG
PerkinElmer Inc.
Pfizer Inc.
Prolong Pharmaceuticals LLC
Sangamo Therapeutics Inc.
Sysmex Corporation
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Recent Developments:
In August 2022, bluebird bio Inc. disclosed information on its U.S. commercial infrastructure to facilitate quick access to ZYNTEGLO, which includes a creative, outcomes-based contract offering and a thorough patient care programme.
In June 2022, Precision BioSciences, Inc. announced that it has signed an agreement (the "Agreement") with Novartis Pharma AG for an exclusive global in vivo gene editing research and development partnership and licence.
In December 2021, Emmaus Life Sciences Inc. released information on Endari(R), a brand name for the business' prescription L-glutamine oral powder used to treat sickle cell illness.
Key Questions Answered in This Report
- 1. What was the size of the global hemoglobinopathies market in 2023?
- 2. What is the expected growth rate of the global hemoglobinopathies market during 2024-2032?
- 3. What has been the impact of COVID-19 on the global hemoglobinopathies market?
- 4. What are the key factors driving the global hemoglobinopathies market?
- 5. What is the breakup of the global hemoglobinopathies market based on the type?
- 6. What is the breakup of the global hemoglobinopathies market based on the treatment?
- 7. What are the key regions in the global hemoglobinopathies market?
- 8. Who are the key players/companies in the global hemoglobinopathies market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Hemoglobinopathies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Thalassemia
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Alpha Thalassemia
- 6.1.2.2 Beta Thalassemia
- 6.1.3 Market Forecast
- 6.2 Sickle Cell Disease
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Treatment
- 7.1 Blood Transfusion
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Stem-cell Transplantation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Analgesics
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Antibiotics
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 ACE Inhibitors
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Hydroxyurea
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Others
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
8 Market Breakup by Test Type
- 8.1 Red Blood Cell (RBC) Count
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Genetic Testing
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 High Performance Liquid Chromatography (HPLC)
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Hemoglobin Electrophoresis (Hb ELP)
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Hemoglobin Solubility Test
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals and Clinics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Diagnostics Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Bio-Rad Laboratories Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 bluebird bio Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bristol-Myers Squibb Company
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Danaher Corporation
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Emmaus Life Sciences Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.6 Gamida-Cell Ltd.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.7 Global Blood Therapeutics Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.8 Novartis AG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 PerkinElmer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Pfizer Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Prolong Pharmaceuticals LLC
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.12 Sangamo Therapeutics Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.13 Sysmex Corporation
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.13.3 Financials
- 15.3.13.4 SWOT Analysis
- 15.3.1 Bio-Rad Laboratories Inc.
